Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
NCT07093710

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Led by Sun Yat-sen University · Updated on 2025-12-31

101

Participants Needed

1

Research Sites

205 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of golidocitinib combined with mitoxantrone hydrochloride liposome or chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma

CONDITIONS

Official Title

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntarily agree to participate and sign informed consent
  • Diagnosed with peripheral T-cell lymphoma per 2022 WHO classification based on pathology
  • Have at least one measurable or evaluable lesion per Lugano 2014 criteria
  • Age 18 years or older
  • Expected survival longer than 12 weeks
  • ECOG performance status between 0 and 2
  • Adequate organ and bone marrow function
Not Eligible

You will not qualify if you...

  • Presence of hemophagocytic lymphohistiocytosis (HLH)
  • Lymphoma involvement in the central nervous system or meninges
  • Active infections
  • Uncontrolled cardiac symptoms or diseases
  • Current use of strong CYP3A inducers or inhibitors that cannot be stopped at least one week before treatment
  • Current use of vitamin K antagonists, antiplatelet agents, or anticoagulants that cannot be stopped at least one week before treatment
  • History of HIV infection or AIDS
  • Mental disorders or inability to provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University

Guangzhou, Guangdong, China

Actively Recruiting

Loading map...

Research Team

Q

Qingqing Cai

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here